Figure 3.

Cytotoxicity of compounds 1–12. (A, B) K562 cells were treated for 2 h at the indicated doses (higher doses in (A), lower doses in (B)) of the various hybrid compounds followed by drug removal. Cell survival in MelJuSo (C), human colorectal carcinoma cell line HCT116 (D), human prostate tumor cell line PC3 (E) and DU145 (F), and human glioblastoma cell line U87 (G). Cells were treated for 2 h at indicated dose followed by drug removal. Cell viability was measured by a Cell-Titerblue assay 72 h post-treatment. Data are shown as mean ± SD from three different experiments. (H) Table showing the IC₅₀ values for the different doxorubicin/aclarubicin hybrid compounds for the indicated cell lines. See also Figure S3A, Supporting Information.